Results 11 to 20 of about 496,043 (271)

Muscarinic Receptor Agonists and Antagonists [PDF]

open access: yesMolecules, 2001
A comprehensive review of pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists is presented. The therapeutic benefits of achieving receptor subtype selectivity are outlined and applications in the ...
David R. Kelly, Kenneth J. Broadley
doaj   +2 more sources

The dual-site agonist for human M2 muscarinic receptors Iper-8-naphtalimide induces mitochondrial dysfunction in Saccharomyces cerevisiae [PDF]

open access: yesMicrobial Cell
Glioblastoma is a malignant astrocytic tumor of the brain. A significantly decrease of glioblastoma cell proliferation and survival can be achieved by activating the M2 muscarinic acetylcholine receptor (a G protein-coupled receptor, or GPCR) with two ...
Angela Cirigliano   +11 more
doaj   +2 more sources

Functionally selective and biased agonists of muscarinic receptors

open access: yesPharmacological Research, 2021
Disruption of cholinergic signalling via muscarinic receptors is associated with various pathologies, like Alzheimer's disease or schizophrenia. Selective muscarinic agonists possess therapeutic potential in the treatment of diabetes, pain or Sjögren's syndrome.
Alena Randáková, Jan Jakubík
openaire   +3 more sources

Multitargeting nature of muscarinic orthosteric agonists and antagonists

open access: yesFrontiers in Physiology, 2022
Muscarinic receptors (mAChRs) are typical members of the G protein-coupled receptor (GPCR) family and exist in five subtypes from M1 to M5. Muscarinic receptor subtypes do not sufficiently differ in affinity to orthosteric antagonists or agonists ...
Jaromir Myslivecek
doaj   +3 more sources

Downstream Signaling of Muscarinic M4 Receptors Is Regulated by Receptor Density and Cellular Environment [PDF]

open access: yesPharmacology Research & Perspectives
Multiple muscarinic M4 receptor modulators are currently advancing in clinical development for the treatment of positive symptoms in schizophrenia, including agonists and positive allosteric modulators.
Madeleine Merz   +5 more
doaj   +2 more sources

Is muscarinic receptor agonist effective and tolerant for schizophrenia? [PDF]

open access: yesBMC Psychiatry
Background Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting muscarinic receptors improve symptom management and reduce
Xiaonan Guo   +3 more
doaj   +2 more sources

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates. [PDF]

open access: yesPLoS ONE, 2015
Cholinergic, muscarinic receptor agonists exhibit functional dopamine antagonism and muscarinic receptors have been suggested as possible future targets for the treatment of schizophrenia and drug abuse. The muscarinic ligand (5R,6R)-6-(3-butylthio-1,2,5-
Maibritt B Andersen   +6 more
doaj   +1 more source

Oscillatory calcium release and sustained store-operated oscillatory calcium signaling prevents differentiation of human oligodendrocyte progenitor cells

open access: yesScientific Reports, 2022
Endogenous remyelination in demyelinating diseases such as multiple sclerosis is contingent upon the successful differentiation of oligodendrocyte progenitor cells (OPCs).
Richard A. Seidman   +4 more
doaj   +1 more source

Vibrational spectroscopy analysis of ligand efficacy in human M2 muscarinic acetylcholine receptor (M2R)

open access: yesCommunications Biology, 2021
Katayama et al. report a vibrational spectroscopic study using ATR–FTIR of the human M2 muscarinic acetylcholine receptor (M2R). Their work involves an extensive comparison of agonists, antagonists, and inverse agonists, in which they show that they C ...
Kota Katayama   +8 more
doaj   +1 more source

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β2 Adrenergic Receptor Agonist Navafenterol in Human Small Airways

open access: yesCells, 2023
Bronchodilators and anti-inflammatory agents are the mainstream treatments in chronic obstructive and pulmonary disease (COPD) and asthma.
Joseph Antony Jude   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy